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Summary: Nerve growth factor is a neurotrophic protein which is known to act on sympathetic and sensory
neurons and on the magnocellular cholinergic neurons of the basal forebrain. We quantified nerve growth
factor in human tissues and body fluids by two methods, a rapid and sensitive two-site immunoenzymometric
assay and a bioassay using dissociated chick dorsal root ganglion neurons. The two-site immunoenzymometric
assay detects nerve growth factor in concentrations as low as 0.5—2.5 ng/1. Using a monoclonal antibody to
mouse nerve growth factor, we found that the signal of the antibody for recombinant human nerve growth
factor is about 60 — 90% of the signal for mouse nerve growth factor. As a control for the specificity of our
data, a bioassay for nerve growth factor was performed and the results showed a good correlation. The
highest nerve growth factor concentrations were found in sciatic nerve (2.5 ng/g wet weight), cardiac atrium
muscle (1.5 ng/g wet weight) and in the central nervous system in the hippocampus (1.9 ng/g wet weight).
Lower nerve growth factor concentrations were measured in human sera (0.2 ng/g wet weight). No nerve
growth factor was detectable in cerebrospinal fluid. The distribution of human nerve growth factor-rich tissues
is similar to that reported for rat tissues.
Introduction _, . r, ,, r .The genomic sequence of human nerve growth factor
Nerve growth factor is a neurotrophic protein which has been determined (6) and small quantities of bio-
is synthesized by target tissues of nerve growth factor- logically active recombinant human nerve growth fac-
sensitive neurons, selectively taken up by the nerve tor have already been produced (Genentech, USA),
terminals and transported retrogradely to the cell Since the sequence homology between murine and
bodies. Nerve growth factor has been shown to act mature human nerve growth factor is 86% on the
on sympathetic and neural crest-derived sensory neu- nucleotide level and 90% on the amino acid level (6),
rons in the peripheral nervous system as well as on a relatively high immunological cross-reactivity is to
the magnocellular cholinergic neurons of the basal be expected. Since the levels of nerve growth factor
forebrain (for review, see I.e. (1—3)). It has been in tissues are extremely low in general, there is a need
suggested that nerve growth factor is involved in the for a highly sensitive test system. The bioassay for
neuropathology of Alzheimer's disease (4). In the pe- nerve growth factor, which is based on the neuro-
ripheral nervous system nerve growth factor may play trophic effect of nerve growth factor on embryonic
a role in the development of autonomic and sensory sensory neurons (7), requires time-consuming cell cul-
neuropathies (5). To clarify whether nerve growth ture procedures and is not suitable for measurements
factor is of physiological or pathological significance in a large number of samples. In competitive immu-
in humans the sensitive and reliable quantification of noradiometric assays, problems arise from the unspe-
endogenous nerve growth factor in human tissues and cific binding of nerve growth factor, for example by
body fluids is a prerequisite. ot2-macroglobulin (8, 9). A two-site immunoradionie-
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trie assay (8) yielded reliable results, but did not attain
the sensitivity required for measurements in human
tissues and body fluids. Two-site immunoenzymo-
metric assays (10, 11) allowed a reliable and sensitive
determination of nerve growth factor concentrations,
but required sophisticated equipment for coating glass
beads or polystyrene tubes with antibody and for
fluorometric measurement of the substrate reaction.
Based on the fluorometric methods described (10,11),
we therefore developed an assay (12, 13) which uses
a chromogenic substrate and which is adapted to
microtitre plates. We employed this method to deter-
mine nerve growth factor concentrations in human
tissues, cerebrospinal fluid and serum using recom-
binant human nerve growth factor as a standard.
Additionally, we examined the specificity of our data
by determining the nerve growth factor concentra-
tions in a sensory neuron bioassay.
Fig. 1. Bioassay for nerve growth factor: Phase (-contrast) mi-
crographs of dorsal root ganglia neurons cultured for
48 h in the presence of recombinant human nerve
growth factor:
(a) 500 ng/1 medium; (b) 5 ng/1 medium
calibration bar = 50 μηι.
Materials and Methods
Two-site immunoenzymometr ic assay
The immunoenzymometric assay was performed as a two-site
assay using the same antibody on both sites, since nerve growth
factor is a homo-dimer consisting of two identical subunits. We
employed the anti mouse nerve growth factor monoclonal an-
tibody MAB 27/21 (10). This antibody, as well as our protocol
for the assay, is now available from Boehringer Mannheim,
Germany. Rigid microtitre plates with high binding capacity
and low variation coefficient (Immuno, Nunc) were coated with
antibody protein overnight at 4 °C (0.3 mg protein per litre
carbonate/bicarbonate buffer 0.05 mol/1; pH 9.7). The plates
were washed with Tris buffer (0.05 mol/1 Tris; 0.15 mol/1 NaCl;
0.005 mol/l MgCl2; 1 g/1 Triton-X-100; pH 7.0) and incubated
at 4 °C overnight with standard solutions of recombinant hu-
man nerve growth factor (2 samples of recombinant human
nerve growth factor, lot 1 and lot 2 were obtained from Ge-
nentech, USA), mouse nerve growth factor (Boehringer Mann-
heim, Germany) or samples, diluted in Tris buffer supplemented
with bovine serum albumin (10 g/1). The concentration of mouse
nerve growth factor in the standard solutions was monitored
by determination of absorbances and by determination of the
half-maximal survival in the bioassay (see below). The micro-
titre plates were washed again before the antibody coupled to
-galactosidase1) (Boehringer Mannheim) was added (400 U/l
buffer, containing 0.05 mol/i Tris, 0.15 mol/l NaCl, 0.005 mol/1
MgCl2, 1 g/1 Triton-X-100, 10 g/1 bovine serum albumin; pH
7.00) and again incubated overnight at 4°C. The indicator
reaction used chlorophenol red- -galactopyranoside (Boehrin-
ger Mannheim) as a chromogenic substrate. After an incubation
period of at least 1 hour, the absorbance was measured at a
test wavelength of 570 nm and a reference wavelength of 630
nm. We determined a standard curve in triplicate on each
microtitre plate.
Bioassay
The in vitro bioassay (fig. 1) is based on the fact that neural
crest-derived embryonic sensory neurons survive and extend




( -D-galactoside galactohydrolase EC
whereas they die rapidly in its absence (7,14—16). Chick dorsal
root ganglia (embryonic day 8) were prepared and collected in
phosphate-buffered saline. The ganglia were incubated in phos-
phate-buffered saline containing 1 g/1 trypsin (Worthington)
and dissociated by gentle trituration with a siliconized Pasteur
pipette. The cells were then suspended in F14 medium (Gibco)
supplemented with horse serum (100 mi/1 medium; Gibco),
preplated in 100 mm dishes (Nunc) in order to remove non-
neuronal cells, then plated into 24-well culture dishes (Costar)
coated with polyornithine (0.5 g/1 in borate buffer; Sigma) and
laminin (4 mg/1; gift from D. Edgar). Samples, or standard
dilutions of mouse nerve growth factor and recombinant human
nerve growth factor in the range of 5—2000 ng/1 medium were
added. The rate of surviving neurons was dose-dependent at
concentrations of nerve growth factor ranging from 20—500
ng/1 culture medium, mouse nerve growth factor showing equiv-
alent activity to that of recombinant human nerve growth
factor. The biological activity of both mouse nerve growth
factor and recombinant human nerve growth factor was
blocked by the specific anti-mouse nerve growth factor mono-
clonal antibody (MAB 27/21). For all measurements, the ad-
dition of MAB 27/21 (in final concentrations of 10-200 μg/l
culture medium) to parallel samples served as a control to
distinguish nerve growth factor-specific survival of the cells
from effects of other uncharacterized factors. The detection
limit of the nerve growth factor bioassay is in the range of 10—
20 ng/1 cell culture medium.
Preparation of tissue samples
Human tissues were obtained from the Department of Forensic
Medicine, University of Munich 4.5-20 h post mortem. Adult
Wistar rats were killed by cervical dislocation. Bovine tissues
were obtained from the municipal slaughterhouse 0.5 and 24 h
post mortem. Tissues were frozen in liquid nitrogen and stored
at -80°C. After homogenization at 4°C in Tris buffer (0.1
mol/1 Tris, 0.3 mol/1 NaCl, 20 g/1 bovine serum albumin; pH
7.0), containing aprotinin (20 000 kallikrein units per litre), 0.1
mmol/1 benzethoniumchloride (Serva), and 1 mmoi/1 benzami-
dine, the homogenates were ultracentrifuged. For the EIA, the
supernatants were diluted 1 + 1 with buffer (containing 0.01
mol/1 MgCl2 and 2 g/L Triton-X-100; p H 7.0). For the biosassay,
the supernatants were diluted witn F14 medium containing
horse serum (100 mi/1 medium; Gu5co) and filtered using 2 μπι
filters (Amicon). Unselected sera and cerebrospinal fluid sam-
ples were freshly obtained continuously from our diagnostic
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laboratory. For the bioassay, sera were incubated for 30 minutes
at 51 °C to remove cytotoxic complement activity. Final dilu-
tions of samples ranged between 1 : 10 and 1 :20. For all
samples the recovery of nerve growth factor was determined
by adding 0.05—0.5 pg/1 recombinant human nerve growth
factor to one part of the homogenate before the homogenates
were ultracentrifuged and by calculating the fraction of recov-
ered nerve growth factor. False positive results in a two-site
assay might be found when anti-mouse IgG present in a sample
„crosslinks" the first and second monoclonal antibody. We
ruled out this possibility by incubating samples and standards
with unspecific monoclonal antibodies (Blockierungsreagenz
CK 33, available on request from Boehringer Mannheim) in
different concentrations from 0.6—42 mg/1 in order to bind
anti-mouse IgG.
Results
An immunoenzymometric assay for nerve growth fac-
tor based on a chromogenic detection system using
-galactosidase and chlorophenol red- -galacotopyr-
anoside was developed. In order to adapt the assay
to microtitre plates, different types of plates including
vinyl, polystyrene and activated polystyrene plates
were compared, and activated polystyrene plates were
selected for highest binding capacity. Coating concen-
trations for the nerve growth factor antibody and
nerve growth factor antibody- -galcatosidase conju-
gate were optimized. For blocking the plates after
antibody adsorption, buffers containing bovine serum
albumin, horse serum, rat serum and ovalbumin were
compared, and it was found that bovine serum al-
bumin in a concentration of 10 g/1 yielded the best
blocking results. For the incubation step with nerve
growth factor, different buffer, pH and detergent con-
ditions were tested; it was found that coating at pH
9.7 and incubation at pH 7.0 using the detergent
Triton-X-100 gave the best results.
Furthermore, all incubation steps were performed
with various combinations of the following incubation
conditions: incubation at 4°C overnight, at room
temperature for two hours, or at 37 °C for two hours.
All of these variations yielded standard curves, but
for all incubation steps, incubation at 4 °C overnight
yielded the lowest and incubation at 37 °C for two
hours yielded the highest standard deviations for the
triplicate measurements. We therefore decided to per-
form all measurements with human nerve growth
factor by incubating at 4 °C overnight, since in human
tissues relatively low nerve growth factor concentra-
tions near the detection limit of the assay were ex-
pected. Nevertheless, it is possible to perform the
assay by incubating for two hours at room tempera-
ture and thus achieve good results in the medium
range of sensitivity within.
Under these optimized assay conditions the detection
limit of the nerve growth factor assay was 0.5 ng/1
(the detection limit was defined as three standard
deviations of the blank signal). Figure 2 shows a
typical standard curve. When the more rapid assay
protocol with incubation at room temperature was
used, the detection limit was 2.5 ng/1. The intra-assay
variance of the optimized assay was determined by
assaying a sample 18 times on one microtitre plate.
The inter-assay variance was estimated by analysis of
4 different samples in 18 consecutive runs. The repro-
ducibility is given in table 1. To examine the specificity
of the assay, insulin and lysozyme were tested as
antigens. Neither of these gave a signal. When com-
paring mouse nerve growth factor and recombinant
human nerve growth factor, the signal for recombi-
nant human nerve growth factor was about 60% of
the signal for the same concentration of mouse nerve
growth factor in lot 1 of human nerve growth factor
and 90% of the signal of mouse nerve growth factor
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Fig. 2. Typical standard curve of the enzyme immunoassay for
nerve growth factor for measurements in the lower range
of sensitivity.
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Fig. 3. Comparison of Standard curves for mouse nerve growth
factor (mNGF) and recombinant human nerve growth
factor (rhNGF) from lot 2. The data for the two graphs
were determined on the same microtitre plate.
whether this difference is due to different concentra-
tions of recombinant human nerve growth factor in
the two samples received, we tried to further evaluate
the nerve growth factor concentration in the samples
by bioassay and measurement of optical density, but
the amount of recombinant human nerve growth fac-
tor we could obtain from the two lots was so small
that these experiments were not possible. Figure 3
shows a comparison of the standard curves of mouse
nerve growth factor and recombinant human nerve
growth factor from lot 1.
For testing samples in the bioassay it is necessary to
remove cytotoxic complement activity by incubating
the samples for 30 minutes at 51 °C. In order to find
out whether this incubation leads to a degradation of
nerve growth factor we assayed samples before and
after incubation in the immunoenzymometric assay.
There was a decrease of 14% in the nerve growth
factor concentration in tissue homogenates and of
22% in serum samples. This decrease was compen-
sated for in each sample by the calculation of the
recovery of nerve growth factor, which was exoge-
nously added before the incubation step (as described
in the section, preparation of tissue samples). In order
to quantify a possible decrease of nerve growth factor
in post mortem tissues, we determined the nerve
growth factor concentrations in rat heart, sciatic
nerve, hippocampus and the rest of the brain imme-
diately post mortem and 6 and 24 hours post mortem
and in bovine hippocampus, temporal cortex, occip-
ital cortex and spinal cord 0.5 and 24 hours post
mortem. When preparing the tissue samples, it was
noted that rat brain tissues 6 and 24 hours post
mortem already shqwed macroscopic colliquative
changes, whereas rat heart, bovine tissues and human
post mortem tissues appeared macroscopically intact.
In bovine tissues and rat heart tissues no relevant
decrease in nerve growth factp^ content was found.
The mean nerve growth factor levels in rat nervous
tissues 6 hours post mortem were 21% lower than
immediately post mortem; 24 hours post mortem
nerve growth factor levels had decreased by 37%.
Nerve growth factor determinations in rat heart 0, 6
and 24 hours post mortem, bovine brain tissues 0.5
and 24 hours post mortem and human tissues 4.5 and
20 hours post mortem showed no relevant differences
in nerve growth factor content related to the period
post mortem.
Nerve growth factor concentrations were determined
in various human post mortem tissues. The recovery
of exogenously added recombinant human nerve
growth factor was in the range of 70 to 100%. Nerve
growth factor measurements in human heart atrium
muscle, skeletal muscle, sciatic nerve, temporal cortex,
hippocampus, and cerebellum were performed by the
immunoenzymometric assay and the bioassay in par-
allel. Relatively high nerve growth factor concentra-
tions were found in sciatic nerve and cardiac atrium
muscle. In the central nervous system, the highest
nerve growth factor concentrations were measured in
the hippocampus (tab. 2).
When parallel measurements using immunoenzymo-
metric assay and bioassay were performed in human
sera and cerebrospinal fluid samples, the recovery of
exogenously added recombinant human nerve growth








































. Values given are means ± standard deviation. For tissues, five
independent experiments (involving samples from 5 different
individuals) were performed, each involving triplicate determi-
nations. For body fluids, the number of independent experi-
ments (n) is given in parenthesis; each experiment was per-
formed in triplicate.
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factor was 50 to 110%. Nerve growth factor concen-
trations were in the range of 200 ng/1 in serum. No
nerve growth factor was detectable in cerebrospinal
fluid (tab. 2). Since the body fluids were diluted by a
factor of 1 :10 for the assays, the limit of nerve growth
factor detection was about 20 ng/1 sample in the EIA
and 150 ng/1 sample in the bioassay.
Discussion
We optimized an immunoenzymometric assay to per-
mit the detection of nerve growth factor in concen-
trations as low as 0.5 to 2.5 ng/1. The assay can be
carried out in microtitre plates and this permits rapid
handling of a large number of samples. Since the
indicator reaction uses a chromogenic substrate, it
can be followed photometrically and there is no need
for sophisticated equipment. The signal for recombi-
nant human nerve growth factor in the assay varied
in the range of 60 to 90% of the signal for mouse
nerve growth factor in different lots of recombinant
human nerve growth factor. This affinity and sensi-
tivity should be sufficient for sensitive quantification
of human nerve growth factor, since the nerve growth
factor concentrations reported, for example in rat
tissues, are in the ränge of 0.1 —1.0 ng/g wet weight
(10, 17). To examine the specificity, insulin, which
shows partial sequence homologies with nerve growth
factor (6), and lysozyme, which is a strongly basic
protein like nerve growth factor, were tested and gave
no signal in the assay. When we measured nerve
growth factor in rat, bovine and human tissues at
different times in the first 24 hours post mortem, we
found no relevant decrease in nerve growth factor
content, except in rat brain tissues, where the decrease
is probably due to the pronounced colliquative
changes.
We quantified nerve growth factor in human tissues
and body fluids by two different methods; the im-
munoenzymometric assay and a nerve growth factor
bioassay using dissociated chick sensory neurons. The
nerve growth factor bioassay serves as a control for
the specificity of the EIA, since the signal depends on
the binding of nerve growth factor to its receptor on
cells in culture; the receptor binding site of the nerve
growth factor molecule has been highly conserved
during the evolution of vertebrates (7). We found
comparable results for the immunoenzymometric as-
say and bioassay measurements.
The highest nerve growth factor concentrations were
found in sciatic nerve, which contains sensory fibres,
and in heart atrium muscle, which is sympathetically
innervated. In the central nervous system the highest
nerve growth factor levels were measured in hippo-
campus and cortex, which are target tissues of the
magnocellular cholinergic system of the basal fore-
brain. This means that the nerve growth factor con-
centration correlates with the physiological distribu-
tion of nerve growth factor-sensitive neurons and their
target tissues. The observed distribution of nerve
growth factor-rich tissues is similar to that reported
for rat tissues (10, 17), which was also confirmed by
our immunoenzymometric assay.
In comparison with nerve growth factor levels in
tissues containing nerve growth factor-sensitive neu-
rons, relatively low nerve growth factor concentra-
tions in the range of 200 ng/1 were measured in human
sera, while the signal was not detectable in cerebro-
spinal fluid samples. In early studies using one-site
immunoradiometric assay, much higher nerve growth
factor levels were detected in mouse sera, but these
results could not be confirmed by bioassay or two-
site immunoradiometric assay (8). Bioassay and two-
site immunoradiometric assay measurements are lim-
ited by the sensitivity of these assays, but they showed
that the nerve growth factor concentration was lower
than 5000 ng/1 by the two-site immunoradiometric
assay and lower than 2000 ng/1 serum by the dorsal
root ganglion bioassay (8). Beck et al. (18), using a
more sensitive two-site immunoradiometric assay,
found that the nerve growth factor levels in human
serum are lower than 500 ng/1. Stephani et al. (19)
evaluated serum nerve growth factor levels with a
sensory neuron bioassay, and reported concentrations
of 200 to 1000 ng/1, in the same range as our results.
These low but measurable nerve growth factor levels
in human body fluids indicate that the primary func-
tion of nerve growth factor is a local trophic effect,
but do not exclude an additional systemic effect.
To determine whether nerve growth factor has a path-
ological or physiological significance in humans, nerve
growth factor concentrations can now be determined
in a relatively large number of human sera, cerebro-
spinal fluid samples and post mortem tissues and
correlated with the clinical data. Monoclonal anti-
bodies against human nerve growth factor should be
developed as soon as suitable quantities of recombi-
nant human nerve growth factor are available.
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